ESMO 2022 | Potential role of ctDNA for early-stage breast cancer

Oleg Gluz, MD, Evang. Krankenhaus “”Bethesda”” Klinik, Mönchengladbach, Germany, discusses the use of circulating tumor cells (CTCs) as a good prognostic marker for early breast cancer, but highlights their limitations. Dr Gluz also talks on the potential of ctDNA and liquid biopsy to aid treatment decisions for early breast cancer, especially in the adjuvant setting. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.